|Year : 2021 | Volume
| Issue : 6 | Page : 32-33
Recovery of alopecia universalis with associated nail dystrophy treated with tofacitinib: A 6-year-old child's case report
Skin Care Clinic, Opposite Government Hospital, Chandrapur, Maharashtra, India
|Date of Submission||07-Sep-2021|
|Date of Acceptance||19-Oct-2021|
|Date of Web Publication||22-Nov-2021|
Skin Care Clinic, Lala Raghuwarlal Complex, 1st Floor, Near Church, Opposite Government Hospital, Chandrapur, Maharashtra
Source of Support: None, Conflict of Interest: None
| Abstract|| |
An emerging treatment modality whose established efficacy in systemic inflammatory diseases is now being actively explored for cutaneous disorders: tofacitinib, an oral Janus kinase inhibitor, is one such treatment. Alopecia universalis has been reported to improve with the use of tofacitinib in various case reports and case series. Nail dystrophy is a diverse skin disorder that has been linked to autoimmune illnesses such as psoriasis and psoriatic arthritis in certain subtypes. Alopecia areata and alopecia universalis are also commonly associated with nail dystrophy. In the present case report, we see that there are also improvements in nail dystrophy in the patient with alopecia universalis who is using tofacitinib.
Keywords: Alopecia areata, alopecia universalis, tofacitinib
|How to cite this article:|
Dube V. Recovery of alopecia universalis with associated nail dystrophy treated with tofacitinib: A 6-year-old child's case report. Int J Trichol 2021;13:32-3
|How to cite this URL:|
Dube V. Recovery of alopecia universalis with associated nail dystrophy treated with tofacitinib: A 6-year-old child's case report. Int J Trichol [serial online] 2021 [cited 2022 Dec 8];13:32-3. Available from: https://www.ijtrichology.com/text.asp?2021/13/6/32/330779
| Introduction|| |
Alopecia universalis (type of alopecia areata) is an autoimmune disease that causes hair loss on the scalp and body due to chronic hair follicle inflammation mediated by CD8+ T-cells. Alopecia areata affects 1%–2% of adults and 20% of children under the age of 16., Nail degeneration, including nail pitting, trachyonychia, onychorrhexis, red staining of the lunulae, onycholysis, onychomadesis, and Beau lines are common in AA and variants. Inflammation caused by T cells may be reduced by Janus kinase inhibitors, which are used for rheumatoid arthritis and psoriasis. Tofacitinib treatment regrows hair in alopecia areata patients by helping hair follicles revert to anagen phase. Case studies, have shown that tofacitinib may help with nail dystrophy caused by alopecia areata. In this report, we present a patient with AA universalis and nail dystrophy who was treated with tofacitinib.
| Case Report|| |
A 6-year-old girl presented to our clinic with a 2-year history of hair loss. Prior to therapy, the patient had seen three to four dermatologists but lost the records. Along with extensive hair loss on the scalp, eyelashes, and eyebrows, the patient was hyperactive and short [Figure 1]a. She had dystrophic fingernails toenails with erythematous areas (striated lunulae), pitting, and nail fragility [Figure 2]a. No other systemic abnormalities were found. Alopecia universalis with nail degeneration was diagnosed clinically. Minoxidil 2% solution was initially used with bimatoprost. After the second appointment, tofacitinib 2.5 mg daily single oral dose was administered due to lack of improvement. All examinations, including complete blood count, serum creatinine, liver function test, lipid profile, HBsAg, HCV, HIV 1 and 2, Mantoux test, tuberculosis interferon gold, and thyroid functions, were all normal prior to starting tofacitinib. Patient was also referred to a geneticist to rule out Down's syndrome. Three months into treatment, 50% of the scalp's hair grew [Figure 1]b, and the nails improved [Figure 2]b. All other medications were discontinued after 3 months, except for tofacitinib. Near-complete hair growth on the scalp, eyebrows, and eyelashes was seen after 6 months of treatment [Figure 1]c. After 6 months of tofacitinib treatment, nail irregularities [Figure 2]c and pain were gone. Subsequent investigations were normal. No side effects were seen due to the medication.
|Figure 1: Hair changes in patient before and after tofacitinib. (a) Before starting tofacitinib. (b) After 3 months of tofacitinib therapy. (c) After 6 months of tofacitinib therapy|
Click here to view
|Figure 2: Nail changes in patient before and after tofacitinib. (a) Before starting tofacitinib. (b) After 3 months of tofacitinib therapy. (c) After 6 months of tofacitinib therapy|
Click here to view
| Discussion|| |
In our case, nail dystrophy coexisted with alopecia universalis. The connection between nail dystrophy and alopecia areata has been extensively documented in the medical literature.,,, Because the nail matrix, like the hair follicle, is a keratin-producing structure, decreasing the autoimmune response to the hair follicle in AU patients may also benefit the nail bed. Dhayalan and King. and Jaller et al. both found nail alterations in their patients with alopecia universalis. Our patient's hair regrowth was almost complete after 6 months of tofacitinib treatment, which is consistent with the case study by Jaller et al. After 6 months of tofacitinib treatment, the current patient's nail dystrophy improved. Tofacitinib has also been found to aid in the treatment of alopecia and nail dystrophy (Dhalayan and King).
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Alshahrani AA, Al-Tuwaijri R, Abuoliat ZA, Alyabsi M, AlJasser MI, Alkhodair R. Prevalence and clinical characteristics of alopecia areata at a Tertiary Care Center in Saudi Arabia. Dermatol Res Pract 2020;2020:7194270.
Bhardwaj P, Basu D, Podder I, Gharami RC. Clinico-epidemiological profile of childhood alopecia areata along with dermoscopic correlation: A cross-section, observational study. Indian Dermatol Online J 2021;12:250-7. [Full text]
Chelidze K, Lipner SR. Nail changes in alopecia areata: An update and review. Int J Dermatol 2018;57:776-83.
Ramot Y, Zlotogorski A. JAK inhibitors for the treatment of alopecia areata. Harefuah 2020;159:38-42.
Shivanna CB, Shenoy C, Priya RA. Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients. Int J Trichology 2018;10:103-7.
Dhayalan A, King BA. Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis. JAMA Dermatol 2016;152:492-3.
Jaller JA, Jaller JJ, Jaller AM, Jaller-Char JJ, Ferreira SB, Ferreira R, et al.
Recovery of nail dystrophy potential new therapeutic indication of tofacitinib. Clin Rheumatol 2017;36:971-3.
Jacobsen AA, Tosti A. Trachyonychia and twenty-nail dystrophy: A comprehensive review and discussion of diagnostic accuracy. Skin Appendage Disord 2016;2:7-13.
Litaiem N, Charfi O, Bacha T, Zeglaoui F. Koilonychia in a patient with alopecia areata. J Clin Aesthet Dermatol 2021;14:42-3.
[Figure 1], [Figure 2]